title: Treatment of peripapillary choroidal neovascular membranes with intravitreal bevacizumab.
abstract: OBJECTIVE
  To evaluate the effect of intravitreal injections of bevacizumab in the treatment of peripapillary choroidal neovascular membranes.
  
  
  METHODS
  Interventional case series of patients with active peripapillary choroidal neovascular membranes. Ophthalmological examination included best-corrected visual acuity, fundus biomicroscopy, fluorescein angiography and optical coherence tomography (OCT). Bevacizumab injections (1.25 mg) were repeated monthly for the first 3 months. Re-treatment was considered if there were any signs of membrane activity.
  
  
  RESULTS
  Six eyes of five patients with peripapillary choroidal membranes were included in the study with a mean follow-up of 13 months (range 6 to 16). Bevacizumab was used as the initial treatment in four eyes and to manage recurrences after surgery in the other two. In five eyes, three injections of bevacizumab led to a complete resolution of leakage on fluorescein angiography and OCT. In one eye, membrane activity persisted despite six injections of bevacizumab. Visual acuity improved in five eyes with a mean improvement of four lines (range: 2-10 lines). It deteriorated only in the eye that did not respond to treatment.
  
  
  CONCLUSIONS
  The results of this case series suggest that the intravitreal injection of bevacizumab may be an effective treatment for peripapillary choroidal membranes.
authors.affiliation: Departamento de Oftalmología, Hospital Ramón y Cajal, Madrid, Spain.
authors.forename: M S
authors.initials: MS
authors.lastname: Figueroa
authors.forename: S
authors.initials: S
authors.lastname: Noval
authors.forename: I
authors.initials: I
authors.lastname: Contreras
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D014792:Visual Acuity / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab